Geriatric assessment in older alloHCT recipients: association of functional and cognitive impairment with outcomes

  • Rebecca L. Olin
    Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, CA;
  • Caitrin Fretham
    Center for International Blood and Marrow Transplant Research, National Marrow Donor Program, Minneapolis, MN;
  • Marcelo C. Pasquini
    Center for International Blood and Marrow Transplant Research, Medical College of Wisconsin, Milwaukee, WI;
  • Mukta Arora
    Division of Hematology, Oncology, and Transplant, Department of Medicine, University of Minnesota, Minneapolis, MN;
  • Vijaya R. Bhatt
    Fred and Pamela Buffett Cancer Center, University of Nebraska Medical Center, Omaha, NE;
  • Benjamin Derman
    Section of Hematology/Oncology, Department of Medicine, University of Chicago, Chicago, IL;
  • Sergio A. Giralt
    Adult Bone Marrow Transplantation Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY;
  • Li-Wen Huang
    Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, CA;
  • Thuy Koll
    Division of Geriatrics, Gerontology, and Palliative Medicine, Department of Internal Medicine, University of Nebraska Medical Center, Omaha, NE;
  • Sang Mee Lee
    Department of Public Health Sciences, University of Chicago, Chicago, IL;
  • Richard J. Lin
    Adult Bone Marrow Transplantation Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY;
  • Linda Pang
    Kelsey-Seybold Clinic, Houston, TX;
  • Uday R. Popat
    Department of Stem Cell Transplantation and Cellular Therapy, MD Anderson Cancer Center, Houston, TX; and
  • Daniel J. Weisdorf
    Division of Hematology, Oncology, and Transplant, Department of Medicine, University of Minnesota, Minneapolis, MN;
  • Andrew Artz
    Department of Hematology and Hematopoietic Cell Transplantation, City of Hope Comprehensive Cancer Center, Duarte, CA

抄録

<jats:title>Abstract</jats:title> <jats:p>Use of allogeneic hematopoietic cell transplantation (alloHCT) is increasing in older patients with hematologic malignancies. Studies suggest that geriatric assessment (GA), incorporating functional measures such as instrumental activities of daily living (IADL), delineates subtle age-related impairments that enhance risk-stratification. The objective of this multi-institutional retrospective study was to evaluate the prognostic utility of GA metrics collected pre-alloHCT. Eligibility criteria included age ≥50 and pre-alloHCT GA inclusive of at least IADL. Beyond IADL, additional geriatric metrics were collected where available and included Medical Outcomes Study Physical Health score (MOS-PH), Timed Up and Go (TUG), and cognition by Blessed Orientation Memory Concentration (BOMC). Three hundred thirty subjects were included, with a median age of 63 (range 50 to 77). Impairments were frequent: 36% had at least 1 IADL impairment; 14% had TUG ≥13.5 seconds; and 17% had cognitive impairment (BOMC ≥ 7). Median MOS-PH score was 80. IADL and age were not significantly associated with nonrelapse mortality (NRM) or overall survival (OS). In multivariate analysis, only impaired cognition and Hematopoietic Cell Transplant-Comorbidity Index score ≥3 showed an independent association with 1-year NRM (subdistribution hazard ratio [SHR], 2.36; P = .01; and SHR, 2.19; P = .009, respectively). Cognitive impairment independently conferred inferior 1-year OS (hazard ratio, 1.94; P = .01). In a preplanned subgroup analysis in 224 patients aged ≥60 years, cognitive impairment remained the sole GA metric predictive of NRM (2-year NRM: SHR, 2.72; P = .007). These data suggest that cognitive impairment elevates risk of post-alloHCT NRM in older patients.</jats:p>

収録刊行物

  • Blood Advances

    Blood Advances 4 (12), 2810-2820, 2020-06-23

    American Society of Hematology

被引用文献 (1)*注記

もっと見る

詳細情報 詳細情報について

問題の指摘

ページトップへ